3qdm
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
[[Image:3qdm.png|left|200px]] | [[Image:3qdm.png|left|200px]] | ||
| - | <!-- | ||
| - | The line below this paragraph, containing "STRUCTURE_3qdm", creates the "Structure Box" on the page. | ||
| - | You may change the PDB parameter (which sets the PDB file loaded into the applet) | ||
| - | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | ||
| - | or leave the SCENE parameter empty for the default display. | ||
| - | --> | ||
{{STRUCTURE_3qdm| PDB=3qdm | SCENE= }} | {{STRUCTURE_3qdm| PDB=3qdm | SCENE= }} | ||
===The complex between TCR DMF4 and human Class I MHC HLA-A2 with the bound MART-1(26-35)(A27L) decameric peptide=== | ===The complex between TCR DMF4 and human Class I MHC HLA-A2 with the bound MART-1(26-35)(A27L) decameric peptide=== | ||
| - | |||
| - | <!-- | ||
| - | The line below this paragraph, {{ABSTRACT_PUBMED_21795600}}, adds the Publication Abstract to the page | ||
| - | (as it appears on PubMed at http://www.pubmed.gov), where 21795600 is the PubMed ID number. | ||
| - | --> | ||
{{ABSTRACT_PUBMED_21795600}} | {{ABSTRACT_PUBMED_21795600}} | ||
| Line 22: | Line 11: | ||
==See Also== | ==See Also== | ||
| - | *[[Beta-2 microglobulin]] | + | *[[Beta-2 microglobulin|Beta-2 microglobulin]] |
| - | *[[Major histocompatibility complex]] | + | *[[Major histocompatibility complex|Major histocompatibility complex]] |
==Reference== | ==Reference== | ||
Revision as of 11:02, 25 July 2012
Contents |
The complex between TCR DMF4 and human Class I MHC HLA-A2 with the bound MART-1(26-35)(A27L) decameric peptide
Template:ABSTRACT PUBMED 21795600
About this Structure
3qdm is a 5 chain structure of Beta-2 microglobulin and Major histocompatibility complex with sequence from Homo sapiens. Full crystallographic information is available from OCA.
See Also
Reference
- Borbulevych OY, Santhanagopolan SM, Hossain M, Baker BM. TCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct Mechanisms. J Immunol. 2011 Jul 27. PMID:21795600 doi:10.4049/jimmunol.1101268
Categories: Homo sapiens | Baker, B M. | Borbulevych, O Y. | Cancer | Cross-reactivity | Hla-a2 | Immune system | Mart-1 peptide | Melanoma | Mhc class i | Nonapeptide | Tcr dmf4 | Tcr dmf5
